Keytruda

Flexibility and adaptation concept Arrows on cubes following a flexible path
Biotech

'One of the lucky few': Bicara CEO on last year's $326M IPO

“We continue to operate as if we're in a world where financings are hard to achieve,” CEO Claire Mazumdar said after Bicara's $362 million 2024 IPO.
Gabrielle Masson Apr 14, 2025 3:59pm
share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm
Graphic of arrows missing the target

Merck's LAG-3 combo fails colorectal cancer phase 3 study

Sep 25, 2024 8:35am
Male and female superheroes posing in fluttering cloaks

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

Sep 14, 2024 2:30am
long shot miss basketball hoop fail shoot

Merck stops phase 3 TIGIT trial in lung cancer for futility

Aug 8, 2024 7:49am
step up climb ladder sky hang on rung

Immutep regains pep as cancer subgroup data show path forward

Jul 12, 2024 9:35am